Conclusions
To conclude, our results demonstrate that treatment with
sofosbuvir/daclatasvir is highly effective in liver fibrosis regression
in HCV-infected cirrhotic patients. Furthermore, HCV eradication in
patients with higher levels of hepatic steatosis led to improvement in
steatosis (CAP value). Future studies with larger sample size, longer
follow-up period, and more precise methods for liver histology
assessment are required to strengthen the current findings, overcome
limitations, and elucidate all affective factors contributing to liver
fibrosis regression in chronic HCV patients receiving DAAs therapy.